Compare · CRWD vs ORPH
CRWD vs ORPH
Side-by-side comparison of CrowdStrike Holdings Inc. (CRWD) and Orphazyme A/S (ORPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CRWD and ORPH operate in Computer Software: Prepackaged Software (Technology), so they compete in similar markets.
- CRWD is the larger of the two at $194.34B, about 1109.8x ORPH ($175.1M).
- CRWD has hit the wire 19 times in the past 4 weeks while ORPH has been quiet.
- CRWD has more recent analyst coverage (25 ratings vs 0 for ORPH).
- Company
- CrowdStrike Holdings Inc.
- Orphazyme A/S
- Price
- $190.86+3.10%
- $0.86-5.49%
- Market cap
- $194.34B
- $175.1M
- 1M return
- -1.19%
- -
- 1Y return
- +70.91%
- -
- Industry
- Computer Software: Prepackaged Software
- Computer Software: Prepackaged Software
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2020
- News (4w)
- 19
- 0
- Recent ratings
- 25
- 0
CrowdStrike Holdings Inc.
CrowdStrike Holdings, Inc. provides cloud-delivered solutions for endpoint and cloud workload protection in the United States, Australia, Germany, India, Israel, Romania, and the United Kingdom. It offers 19 cloud modules on its Falcon platform through a software as a service subscription-based model that covers various security markets, such as corporate workload security, security and vulnerability management, managed security services, IT operations management, threat intelligence services, identity protection, and log management. The company primarily sells its platform and cloud modules through its direct sales team. CrowdStrike Holdings, Inc. was incorporated in 2011 and is headquartered in Sunnyvale, California.
Orphazyme A/S
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.
Latest CRWD
- PRESIDENT AND CEO Kurtz George sold $3,611,808 worth of shares (20,000 units at $180.59), decreasing direct ownership by 0.25% to 8,103,544 units (SEC Form 4)
- PRESIDENT AND CEO Kurtz George sold $3,667,195 worth of shares (20,000 units at $183.36), decreasing direct ownership by 0.25% to 8,123,544 units (SEC Form 4)
- Loop Capital initiated coverage on CrowdStrike with a new price target
- PRESIDENT AND CEO Kurtz George sold $3,257,882 worth of shares (17,466 units at $186.53), decreasing direct ownership by 0.24% to 8,143,544 units (SEC Form 4)
- A Post-Quantum Security Company Just Planted a Flag in Southeast Asia, Right as Governments Start Mandating the Switch
- PRESIDENT AND CEO Kurtz George sold $1,926,727 worth of shares (10,000 units at $192.67), decreasing direct ownership by 0.12% to 8,163,544 units (SEC Form 4)
- CrowdStrike and Cerebras Partner to Power AI Detection and Response on the World's Fastest Inference
- PRESIDENT AND CEO Kurtz George sold $4,085,238 worth of shares (20,000 units at $204.26), decreasing direct ownership by 0.24% to 8,173,544 units (SEC Form 4)
- PRESIDENT AND CEO Kurtz George sold $4,124,930 worth of shares (20,000 units at $206.25), decreasing direct ownership by 0.24% to 8,193,544 units (SEC Form 4)
- Ottawa Just Picked This Small Canadian Company to Represent Its Quantum Technology in Europe
Latest ORPH
- SEC Form 6-K filed by Orphazyme A/S
- SEC Form 20-F filed by Orphazyme A/S
- SEC Form 6-K filed by Orphazyme A/S
- SEC Form 6-K filed by Orphazyme A/S
- SEC Form 6-K filed by Orphazyme A/S
- SEC Form 6-K filed by Orphazyme A/S
- SEC Form NT 20-F/A filed by Orphazyme A/S (Amendment)
- SEC Form 6-K filed by Orphazyme A/S
- SEC Form 6-K filed by Orphazyme A/S
- SEC Form NT 20-F filed by Orphazyme A/S